MARKET

NAVB

NAVB

NAVIDEA BIOPHARM
AMEX

Real-time Quotes | Nasdaq Last Sale

1.570
+0.010
+0.64%
Closed 17:07 09/17 EDT
OPEN
1.580
PREV CLOSE
1.560
HIGH
1.600
LOW
1.500
VOLUME
114.97K
TURNOVER
--
52 WEEK HIGH
3.150
52 WEEK LOW
1.460
MARKET CAP
47.36M
P/E (TTM)
-3.5869
1D
5D
1M
3M
1Y
5Y
BRIEF-Navidea Reports Changes To Board Of Directors Composition
reuters.com · 2d ago
Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition
DUBLIN, Ohio, September 17, 2021--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on September 14, 2...
Business Wire · 2d ago
Navidea Biopharmaceuticals' Board Chair Retires, Replacement Named
MT Newswires · 3d ago
Navidea Biopharma (NAVB) Reports Q2 Loss, Misses Revenue Estimates
Navidea (NAVB) delivered earnings and revenue surprises of 0.00% and -56.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/11 21:15
BRIEF-Navidea Biopharmaceuticals Q2 Revenue $261,000
reuters.com · 08/11 20:49
Navidea Biopharm EPS in-line, misses on revenue
Navidea Biopharm (NYSE:NAVB): Q2 GAAP EPS of -$0.09 in-line. Revenue of $0.26M (-3.7% Y/Y) misses by $0.34M. Press Release
Seekingalpha · 08/11 20:03
Navidea Biopharmaceuticals Q2 Loss Shrinks Even as Revenue Falls
MT Newswires · 08/11 16:23
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the...
Benzinga · 08/08 14:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NAVB. Analyze the recent business situations of NAVIDEA BIOPHARM through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NAVB stock price target is 6.50 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 32
Institutional Holdings: 742.82K
% Owned: 2.46%
Shares Outstanding: 30.16M
TypeInstitutionsShares
Increased
7
158.08K
New
5
36.74K
Decreased
8
25.91K
Sold Out
24
84.02K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
S. Kathryn Rouan
Chief Executive Officer/Chief Financial Officer/Chief Operating Officer/IR Contact Officer
Jed Latkin
Other
Michael Rosol
Director
John Scott
Independent Director
Amit Bhalla
Independent Director
Claudine Bruck
Independent Director
Alexander Cappello
Independent Director
Malcolm Witter
No Data
  • All
  • Financials
  • Insiders
More
About NAVB
Navidea Biopharmaceuticals, Inc. (Navidea) is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company focuses on two drug product diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694, and therapeutic development programs, including therapeutic applications of Manocept platform. It also focuses on developing multiple precision-targeted products based on Manocept platform by identifying the sites and pathways of undetected disease and provide diagnostic services. Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the product developed and commercialized by Navidea based on the platform.

Webull offers kinds of Navidea Biopharmaceuticals Inc stock information, including AMEX:NAVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NAVB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NAVB stock methods without spending real money on the virtual paper trading platform.